LOGIN  |  REGISTER
Surmodics

Merit Medical Systems (NASDAQ: MMSI) Stock Quote

Last Trade: US$76.51 0.25 0.33
Volume: 456,449
5-Day Change: -4.13%
YTD Change: 0.72%
Market Cap: US$4.420B

Latest News From Merit Medical Systems

Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-year Q4 2023 constant currency revenue* up 10.3% year-over-year Q4 2023 constant currency revenue, organic* up 8.3% year-over-year Q4 2023 GAAP operating margin of 10.4%, compared to 10.4% in Q4 2022 Q4 2023 non-GAAP operating margin* of 18.2%, compared to 17.8% in Q4 2022 Q4 2023 GAAP EPS $0.47, compared to $0.58 in Q4 2022 Q4 2023 non-GAAP EPS* $0.81, compared... Read More
SOUTH JORDAN, Utah, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today introduced its Continued Growth Initiatives Program and related financial targets for the three-year period ending December 31, 2026. Merit’s new multi-year financial targets are: Total revenue increase at a compound annual growth rate (CAGR) of 5% to 7%... Read More
SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. ( NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the SCOUT ® MD™ Surgical Guidance System. The release of the new guidance system demonstrates Merit’s ongoing leadership in oncology and marks a significant advancement in breast cancer care. SCOUT MD broadens... Read More
SOUTH JORDAN, Utah, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for the treatment of... Read More
2023 reported preliminary unaudited revenue in the range of approximately $1.255 billion - $1.259 billion, up approximately 9.0% - 9.4% year-over-year 2023 preliminary unaudited constant currency revenue* in the range of up approximately 9.6% - 9.9% year over year 2023 financial results and 2024 guidance to be released February 28, 2024 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this... Read More
SOUTH JORDAN, Utah, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Merit Chairman and CEO, Fred Lampropoulos, is scheduled to present at the J.P. Morgan 42 nd Annual Healthcare Conference on January 8, 2024, at 4:30pm PT. A live audio webcast of the conference presentation will be available on the investor... Read More
SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as... Read More
SOUTH JORDAN, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to... Read More
SOUTH JORDAN, Utah, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably... Read More
Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-year Q3 2023 constant currency revenue* up 9.7% year over year Q3 2023 constant currency revenue, organic* up 7.1% year-over-year Q3 2023 GAAP operating margin of 11.1%, compared to 6.5% in Q3 2022 Q3 2023 non-GAAP operating margin* of 18.3%, compared to 16.1% in Q3 2022 Q3 2023 GAAP EPS $0.44, compared to $0.27 in Q3 2022 Q3 2023 non-GAAP EPS* of $0.75, compared... Read More
SOUTH JORDAN, Utah, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the expansion of its Maestro Microcatheter product line to now include a new longer length for radial embolization procedures. The Maestro is part of a comprehensive offering of embolotherapy solutions, which includes Embosphere® Microspheres,... Read More
SOUTH JORDAN, Utah, Oct. 05, 2023 (GLOBE NEWSWIRE) - - Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2023, after the close of the stock market on Thursday, October 26, 2023. Merit will hold its investor conference call on the same day (Thursday, October 26, 2023) at... Read More
SOUTH JORDAN, Utah, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc . (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of its Aspira Bottle. The new evacuated drainage bottle is the latest addition to Merit’s drainage portfolio. Offering a wide range of intervention products, solutions, and accessories, the comprehensive portfolio... Read More
SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) to... Read More
Q2 2023 reported revenue of $320.1 million, up 8.5% year-over-year Q2 2023 constant currency revenue* up 9.4% year over year Q2 2023 constant currency revenue, organic* up 9.1% year-over-year Q2 2023 GAAP operating margin of 9.0%, compared to 7.9% in Q2 2022 Q2 2023 non-GAAP operating margin* of 19.9%, compared to 19.1% in Q2 2022 Q2 2023 GAAP EPS $0.35, compared to $0.27 in Q2 2022 Q2 2023 non-GAAP EPS* of $0.81, compared... Read More
SOUTH JORDAN, Utah, July 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2023, after the close of the stock market on Tuesday, July 25, 2023. Merit will hold its investor conference call on the same day (Tuesday, July 25, 2023) at 5:00 p.m.... Read More
Acquisitions broaden Merit’s therapeutic platform with diverse dialysis product solutions and expand its access catheter offering Acquisitions projected to add approximately $30 million of revenue, on an annualized basis, in key strategic markets that leverage existing commercial footprint Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include... Read More
SOUTH JORDAN, Utah, June 07, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that it has entered into a new, five-year senior secured credit agreement. The credit agreement includes a revolving credit facility in an aggregate principal amount of up to $700 million and a term loan facility in an aggregate principal amount... Read More
Q1 2023 reported revenue of $297.6 million, up 8.0% compared to Q1 2022 Q1 2023 constant currency revenue, organic* up 9.8% compared to Q1 2022 Q1 2023 GAAP operating margin of 8.9%, compared to 5.5% in Q1 2022 Q1 2023 non-GAAP operating margin* of 16.1%, compared to 14.6% in Q1 2022 Q1 2023 GAAP EPS $0.36, compared to $0.18 in Q1 2022 Q1 2023 non-GAAP EPS* of $0.64, compared to $0.53 in Q1 2022 * Constant currency revenue;... Read More
SOUTH JORDAN, Utah, April 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2023, after the close of the stock market on Wednesday, April 26, 2023. Merit will hold its investor conference call on the same day (Wednesday, April 26, 2023) at 5:00... Read More
SOUTH JORDAN, Utah, March 20, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the expansion of its SwiftNINJA Steerable Microcatheter product line. New sizes include a low-profile 2.4F distal diameter option in 125-cm and new longer 150-cm lengths. The 180-degree articulating microcatheter is designed to provide access... Read More
Q4 2022 reported revenue of $293.4 million, up 5.4% compared to Q4 2021 Q4 2022 constant currency revenue, organic* up 8.2% compared to Q4 2021 Q4 2022 GAAP operating margin of 10.4%, compared to 7.9% in Q4 2021 Q4 2022 non-GAAP operating margin* of 17.8%, compared to 17.4% in Q4 2021 Q4 2022 GAAP EPS $0.58, compared to $0.36 in Q4 2021 Q4 2022 non-GAAP EPS* of $0.79, compared to $0.71 in Q4 2021 * Constant currency revenue;... Read More
SOUTH JORDAN, Utah, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the FDA has granted Breakthrough Device Designation for the SCOUT MD Surgical Guidance System. The SCOUT MD is the latest step in Merit’s ongoing commitment and leadership in advancing oncology care. SCOUT MD expands Merit’s portfolio of... Read More
SOUTH JORDAN, Utah, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2022, and issue fiscal year 2023 guidance after the close of the stock market on Wednesday, February 22, 2023. Merit will hold its investor conference... Read More
SOUTH JORDAN, Utah, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the successful enrollment of the first patient in its prospective, observational study of EmboCube Embolization Gelatin used to control bleeding or hemorrhage. Uncontrolled bleeding, particularly as a result of trauma, is a leading cause of... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB